生产企业：GSK
Efimosfermin alfa (BOS-580) is a once-monthly fibroblast growth factor 21 (FGF21) analog originated by Boston Pharmaceuticals and acquired by GSK, which is expected to pay $1.2 billion upfront plus up to $800 million in milestone payments for the asset. It is a Phase III-ready candidate for steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease (ALD), with first launch expected in 2029.
Efimosfermin alfa (BOS-580) is a once-monthly fibroblast growth factor 21 (FGF21) analog originated by Boston Pharmaceuticals and acquired by GSK, which is expected to pay $1.2 billion upfront plus up to $800 million in milestone payments for the asset. It is a Phase III-ready candidate for steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease (ALD), with first launch expected in 2029.
Fibroblast growth factor 21 (FGF21) analog
共 3 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
